While considerable efforts have been contributed to developing novel HDAC inhibitors for cancer treatment, hydroxamate-based HDAC inhibitors have gained growing attention due to their broad-spectrum anti-tumor activities 7–10. The gene discussed is HDAC9; the disease is cancer.